fell 3.54% after it announced its decision to not initiate a phase III study on its pipeline candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time. The company’s decision was based on a review of recent updates regarding the efficacy of COVID-19 vaccine candidates and other treatment options.
Shares of the company have increased 45.2% year to date against the
’s decline of 0.6%.
The company is continuing to assess the rapidly evolving clinical and commercial landscape related to the pandemic and may consider other options to evaluate itolizumab in COVID-19 patients, including government research initiatives.
The company will evaluate, develop and prioritize its resources for the expansion and acceleration of itolizumabfor the treatment of acute graft-versus-host disease (aGVHD) based on positive interim data on the same. The company also plans to advance the candidate for the treatment of lupus / lupus nephritis and uncontrolled asthma studies.
We note that this month, the FDA gave Emergency Use Authorization (EUA) to
antibody cocktail, casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19. The FDA grants EUA to medicines that may help diagnose, treat or prevent a life-threatening disease when adequate and approved alternatives are not available.
is also making painstaking efforts to develop several potential neutralizing antibodies for the treatment of COVID-19. In November 2020, Lilly’s antibody therapy – bamlanivimab was granted an emergency use authorization by the FDA for treating COVID-19, widening the access to a treatment that early data suggest is effective in keeping people infected with coronavirus out of the hospital. Meanwhile, in October,
Vir Biotechnology, Inc.
and GlaxoSmithKline plc. announced the global expansion to phase III of the COMET-ICE study evaluating investigational monoclonal antibody, VIR-7831, for the early treatment of COVID-19 in patients who are at high risk of hospitalization.
Equillium currently carries a Zacks Rank #3 (Hold). You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year. These 7 were selected because of their superior potential for immediate breakout.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report